阿托伐他汀联合尼莫地平对轻度脑小血管病性认知功能损害的疗效研究

The Clinical Efficacy and Impact of Atorvastatin Combined with Nimodipine on Mild Cognitive Impairment Caused by Cerebrovascular Disease

目的探究分析对轻度脑小血管病性认知功能损害患者,联合应用尼莫地平、阿托伐他汀干预后的疗效及生活能力的影响研究。方法选取2023年6月至2023年12月山西医科大学汾阳学院收治的80例轻度脑小血管病性认知功能损害患者,随机划分为研究组与对照组,每组各40例,前者采取阿托伐他汀联合尼莫地平治疗,后者采取控压、控糖常规治疗,比较两组生活能力指标,随访疾病疗效、认知功能。结果治疗后研究组生活能力评分高于对照组,差异有统计学意义(P<0.05);研究组总有效率(97.50%)高于对照组(77.50%),差异有统计学意义(P<0.05);治疗后研究组认知功能评分高于对照组,差异有统计学意义(P<0.05)。结论对轻度脑小血管病性认知功能损害患者予以联合干预,结果证实阿托伐他汀联合尼莫地平治疗可以改善其生活能力指标,提升疾病疗效,改善认知功能,安全性更高,适合用于临床进一步研究和推广。

Objective To explore and analyze the clinical efficacy and impact of the ability to live independently of serving atorvastatin combined with nimodipine on cognitive function impairment in patients with mild cerebrovascular disease.Methods Selecting 80 patients with mild cognitive impairment caused by cerebral small vessel disease admitted to Fenyang College of Shanxi Medical University from June 2023 to December 2023,they were randomly divided into the study group and the control group,with 40 cases in each group.The study group received atorvastatin combined with nimodipine treatment,while the control group received conventional treatment such as pressure and glucose control.The two groups were compared in terms of living ability indicators,disease efficacy,and cognitive function.Results After treatment,the living ability score of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05);The total effective rate of the study group(97.50%)was higher than that of the control group(77.50%),and the difference was statistically significant(P<0.05);After treatment,the cognitive function score of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The combined intervention of atorvastatin and nimodipine was performed on patients with mild cognitive impairment caused by cerebrovascular disease.The results showed that atorvastatin combined with nimodipine treatment can improve their ability to live indicators,enhance disease efficacy,improve cognitive function,and have higher safety.It is suitable for further clinical research and promotion.